1
|
Han SJ, Jung JE, Oh DH, Kim M, Kim JM, Chung KS, Han HS, Lee JH, Lee KT, Jeong HJ, Park IH, Jeon E, Shin JS, Hwang D, Cho AE, Lee DH, Sim T. Identification of highly selective type II kinase inhibitors with chiral peptidomimetic tails. J Enzyme Inhib Med Chem 2022; 37:1257-1277. [PMID: 35484863 PMCID: PMC9067983 DOI: 10.1080/14756366.2022.2068148] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022] Open
Abstract
Identification of highly selective type II kinase inhibitors is described. Two different chiral peptidomimetic scaffolds were introduced on the tail region of non-selective type II kinase inhibitor GNF-7 to enhance the selectivity. Kinome-wide selectivity profiling analysis showed that type II kinase inhibitor 7a potently inhibited Lck kinase with great selectivity (IC50 of 23.0 nM). It was found that 7a and its derivatives possessed high selectivity for Lck over even structurally conserved all Src family kinases. We also observed that 7a inhibited Lck activation in Jurkat T cells. Moreover, 7a was found to alleviate clinical symptoms in DSS-induced colitis mice. This study provides a novel insight into the design of selective type II kinase inhibitors by adopting chiral peptidomimetic moieties on the tail region.
Collapse
Affiliation(s)
- Seo-Jung Han
- Chemical Kinomics Research Center, Korea Institute of Science and Technology, Seoul, Republic of Korea.,Division of Bio-Medical Science & Technology, KIST School, UST, Seoul, Republic of Korea
| | - Jae Eun Jung
- Chemical Kinomics Research Center, Korea Institute of Science and Technology, Seoul, Republic of Korea.,Department of Chemistry, Sogang University, Seoul, Republic of Korea
| | - Do Hee Oh
- Chemical Kinomics Research Center, Korea Institute of Science and Technology, Seoul, Republic of Korea.,Department of Chemistry, Sogang University, Seoul, Republic of Korea
| | - Minsup Kim
- Drug Discovery Institute, inCerebro Co., Ltd., Seoul, Republic of Korea
| | - Jae-Min Kim
- Department of Pharmaceutical Biochemistry, College of Pharmacy, Kyung Hee University, Seoul, Republic of Korea.,Department of Biomedical and Pharmaceutical Sciences, Graduate School, Kyung Hee University, Seoul, Republic of Korea
| | - Kyung-Sook Chung
- Department of Pharmaceutical Biochemistry, College of Pharmacy, Kyung Hee University, Seoul, Republic of Korea
| | - Hee-Soo Han
- Department of Pharmaceutical Biochemistry, College of Pharmacy, Kyung Hee University, Seoul, Republic of Korea.,Department of Life and Nanopharmaceutical Sciences, College of Pharmacy, Kyung Hee University, Seoul, Republic of Korea
| | - Jeong-Hun Lee
- Department of Pharmaceutical Biochemistry, College of Pharmacy, Kyung Hee University, Seoul, Republic of Korea.,Department of Life and Nanopharmaceutical Sciences, College of Pharmacy, Kyung Hee University, Seoul, Republic of Korea
| | - Kyung-Tae Lee
- Department of Pharmaceutical Biochemistry, College of Pharmacy, Kyung Hee University, Seoul, Republic of Korea.,Department of Biomedical and Pharmaceutical Sciences, Graduate School, Kyung Hee University, Seoul, Republic of Korea
| | - Hee Jin Jeong
- Chemical Kinomics Research Center, Korea Institute of Science and Technology, Seoul, Republic of Korea
| | - In Ho Park
- Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.,Institute of Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Republic of Korea
| | - Eunkyeong Jeon
- Institute of Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Republic of Korea.,Department of Microbiology, Yonsei University College of Medicine, Seoul, Republic of Korea
| | - Jeon-Soo Shin
- Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea.,Institute of Immunology and Immunological Diseases, Yonsei University College of Medicine, Seoul, Republic of Korea.,Department of Microbiology, Yonsei University College of Medicine, Seoul, Republic of Korea
| | - Dongkeun Hwang
- Chemical Kinomics Research Center, Korea Institute of Science and Technology, Seoul, Republic of Korea
| | - Art E Cho
- Drug Discovery Institute, inCerebro Co., Ltd., Seoul, Republic of Korea.,Department of Bioinformatics, Korea University, Sejong, Republic of Korea
| | - Duck-Hyung Lee
- Department of Chemistry, Sogang University, Seoul, Republic of Korea
| | - Taebo Sim
- Chemical Kinomics Research Center, Korea Institute of Science and Technology, Seoul, Republic of Korea.,Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea
| |
Collapse
|
2
|
Thoma G, Blanz J, Bühlmayer P, Drückes P, Kittelmann M, Smith AB, van Eis M, Vangrevelinghe E, Zerwes HG, Che J(J, He X, Jin Y, Lee CC, Michellys PY, Uno T, Liu H. Syk inhibitors with high potency in presence of blood. Bioorg Med Chem Lett 2014; 24:2278-82. [DOI: 10.1016/j.bmcl.2014.03.075] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2014] [Revised: 03/24/2014] [Accepted: 03/25/2014] [Indexed: 11/16/2022]
|
3
|
Currie KS, Kropf JE, Lee T, Blomgren P, Xu J, Zhao Z, Gallion S, Whitney JA, Maclin D, Lansdon EB, Maciejewski P, Rossi AM, Rong H, Macaluso J, Barbosa J, Di Paolo JA, Mitchell SA. Discovery of GS-9973, a selective and orally efficacious inhibitor of spleen tyrosine kinase. J Med Chem 2014; 57:3856-73. [PMID: 24779514 DOI: 10.1021/jm500228a] [Citation(s) in RCA: 105] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
Spleen tyrosine kinase (Syk) is an attractive drug target in autoimmune, inflammatory, and oncology disease indications. The most advanced Syk inhibitor, R406, 1 (or its prodrug form fostamatinib, 2), has shown efficacy in multiple therapeutic indications, but its clinical progress has been hampered by dose-limiting adverse effects that have been attributed, at least in part, to the off-target activities of 1. It is expected that a more selective Syk inhibitor would provide a greater therapeutic window. Herein we report the discovery and optimization of a novel series of imidazo[1,2-a]pyrazine Syk inhibitors. This work culminated in the identification of GS-9973, 68, a highly selective and orally efficacious Syk inhibitor which is currently undergoing clinical evaluation for autoimmune and oncology indications.
Collapse
Affiliation(s)
- Kevin S Currie
- Department of Chemistry, ‡Department of Biology, and §Department of Drug Metabolism, Gilead Sciences, Inc. , Branford, Connecticut 06405, United States
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|